• Vaccine Ontology ID: VO_0004047
• Type: Subunit vaccine
• Status: Research
• Antigen: Recombinant ClfA protein (Josefsson et al., 2001).
• ClfA gene engineering:
  • Type: Recombinant protein preparation
  • Description: Expression and purification of recombinant proteins.Vector pCF40 expressed rClfA truncate rClfA40‐559 (Josefsson et al., 2001).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000139
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: NMRI
• Vaccination Protocol: Purified rClfA region A, comprising residues 40–559 (rClfA40‐559), and BSA (Sigma Chemical) were dissolved in physiologic saline and were emulsified 1:1 in Freund's complete adjuvant (Difco Laboratories). In total, 200 μL of the emulsion containing 30 μg of protein was injected subcutaneously (sc) on day −21 ( /group). Booster immunization with 30 μg of protein in physiologic saline:Freund's incomplete adjuvant 1:1 sc was done on day −10 (Josefsson et al., 2001).
• Challenge Protocol: On day 0, the mice were challenged iv with 1.6 x 10^7 cfu/mouse of wild‐type S. aureus strain Newman (Josefsson et al., 2001).
• Efficacy: Mice immunized with rClfA40‐559 had less severe arthritis than did the control BSA‐immunized group throughout the experiment. Both the severity of synovitis and the extent of joint destruction were markedly less pronounced in mice immunized with rClfA40‐559 than in the BSA control group (Josefsson et al., 2001).